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Inhalation of on-demand salbutamol (ODS) several times daily is sometimes the only b2-agonist prescribed in
moderate persistent asthma, whereas a long-acting b2-agonist should be added. This trial aimed to compare the
ecacy of formoterol dry-powder capsule 12mg b.i.d. (Foradil1) and ODS in patients with moderate persistent
asthma treated with inhaled corticosteroids, in the conditions of real practice. Two hundred and fifty-nine patients
were randomized (formoterol; 130; ODS: 129) in this open, parallel-group trial. The mean increases in morning
peak expiratory flow (PEF primary variable) and evening PEF over the 3-month treatment period were statistically
significantly higher with formoterol: +25?7 and +24?1 l min71, respectively vs. +4?5 and +0?5 lmin71
respectively with ODS. The increase in FEV1 was statistically significantly higher with formoterol at months 1
and 3. Formoterol reduced the use of salbutamol as rescue medication by two-thirds. The percentages of symptom-
free days and nights statistically significantly increased with formoterol (+20% and +33% respectively), but did
not significantly change with ODS. Clinically relevant and statistically significant improvement in the mean total
score of the St George’s Hospital Respiratory Questionnaire was observed in the formoterol group. Adverse events
were similar in the two groups. The results show that treatment with formoterol has significant advantages over
ODS in patients with moderate persistent asthma.
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Formoterol is a long-acting b2-agonist bronchodilator
available as dry-powder capsules containing 12 mg of
formoterol fumarate administered via a single dose
breath-actuated inhaler (1). It is mainly used in patients
presenting with moderate or severe persistent asthma
[according to the classification of the Global Initiative for
Asthma (2)] not optimally controlled with inhaled corti-
costeroids, i.e. in case of persistent symptoms or in patients
with nocturnal symptoms or using too many puffs of short-
acting b2-agonists (3).
Contrary to long-acting b2-agonists, the use of short-
acting b2-agonists at a fixed dosage is not recommended (2),
because this has no advantage compared with use on an as-
needed basis (4,5). On-demand short-acting b2-agonists such
as salbutamol are usually the only b2-agonists used for the
treatment of intermittent asthma and mild persistent asthma.Received 27 June 2000 and accepted in revised form 26 September
2000. Published online 11 December 2000.
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0954-6111/01/010064+07 $35?00/0The use of long-acting b2-agonists is not questioned in
patients with severe persistent asthma. In patients with
moderate persistent asthma, on-demand short-acting b2-
agonists are sometimes only prescribed whereas long-
acting b2-agonists are recommended to be introduced.
Formoterol has never been directly compared with a
short-acting b2-agonist given on an on-demand basis, but
with salbutamol given at a fixed dosage of 200mg or 400mg
two or four times daily (6–11), or indirectly during trials
comparing formoterol with a placebo matched to formoterol
in combination with on-demand salbutamol (11,12). How-
ever in this case, results may not be strictly extrapolated
because of the possible interference of the placebo effect.
The aim of this pragmatic study was to directly assess the
ecacy and the safety of formoterol given at the standard
dosage of 12 mg twice daily vs. on-demand (ODS) salbuta-
mol given in patients with a moderate persistent asthma.
Methods
STUDY POPULATION
Male and female outpatients aged 18 years or over with
moderate persistent asthma were eligible for inclusion.# 2000 HARCOURT PUBLISHERS LTD
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corticosteroid (the same product at a stable dose for at least
1 month prior to the first visit) and require daily treatment
with inhaled bronchodilators (taken regularly or on-
demand). The inhaled corticosteroid was kept at a constant
dose throughout the trial, up to the maximal daily dose
permitted in moderate persistent asthma (i.e. 1000 mg of
beclomethasone, 800 mg of budesonide, 500mg of flutica-
sone). However in case of asthma exacerbation, a transient
increase in the daily dose of the inhaled corticosteroid
therapy, a course of oral corticosteroid therapy or a
symptomatic b2-agonist nebulization therapy were allowed.
Asthma was defined according to the criteria of the
American Thoracic Society (13). The FEV1 had to be
superior or equal to 60% of the predicted normal value for
the patient. Reversibility test (increase in FEV1 510% of
the predicted value) had to be documented at the first visit
or within 3 months prior to this visit. Patients had to refrain
from taking salbutamol 6 h before each spirometry.
The patients were excluded if they presented one of the
following criteria: known hypersensitivity to sympathic
amines or to lactose; pregnancy or breast-feeding; women
of childbearing potential who did not use a reliable
contraceptive method; significant change in the regular
asthma medication, asthma exacerbation or respiratory
tract infection in the month prior to the first visit;
incapacity to use a metered-dose inhaler correctly or to
complete the patient diary. Concomitant treatments with
theophylline, anticholinergic bronchodilators and inhaled
or oral b2-agonists other than the trial medications were not
allowed.
STUDY DESIGN
This multicentre study was performed by 42 specialists in
France, from February 1998 to March 1999, as a
randomized, open, parallel-group trial in two groups of
asthmatic patients who were treated for 3 months with
either one dry-powder capsule containing 12mg of for-
moterol fumarate every morning and evening (Foradil1,
Novartis Pharma S.A) with salbutamol as rescue medica-
tion, or ODS via a metered-dose inhaler (100 mg puff71).
The trial had two periods. The first period was a 2- to 3-
week run-in, baseline period during which all patients
received ODS. The second period was a 3-month treatment
period in which patients were assigned at random to one of
the two treatment groups. Centralized phone randomiza-
tion was used to avoid inclusion bias. Patients underwent
five visits during the trial: one at the start of study (visit 1),
a randomization visit (visit 2), then three monthly visits
during treatment (visits 3, 4 and 5). An Ethics Committee
approved the study protocol and all participants gave their
written consent.
CLINICAL ASSESSMENTS
Patients completed a diary card twice daily throughout the
whole trial. The following data were recorded: pre-dose
peak expiratory flow (PEF) (morning and evening) using amini-Wright peak flow meter; night-time asthma symptom
score (0¼no breathing problems; 1=one waking up
because of breathing problems, but no use of rescue
medication; 2¼one waking up because of breathing
problems, controlled by rescue medication; 3¼more than
one waking up because of breathing problems, controlled
by rescue medication; 4¼dicult sleep because of breathing
problems, despite use of rescue medication); daytime
asthma symptom score (0¼no breathing problems at all,
activity not restricted; 1¼breathing problems with little or
no discomfort, and no activity restriction; 2¼breathing
problems with some discomfort and limitation of strenuous
activity; 3¼breathing problems with discomfort and limita-
tion of routine activity; 4¼breathing problems at rest with
major discomfort and limitation of routine activity);
number of inhalations of rescue medication (salbutamol)
used during the night and during the day.
A spirometry was performed at each visit before the
morning dose of trial medication and the best of three
determinations of FEV1 was recorded.
The St George’s Hospital Respiratory Questionnaire
(SGRQ) was used to measure quality of life. The SGRQ
was self-administered by the patient at the investigator’s
site at visits 2 (baseline) and 5 (after 3 months). The total
score was calculated, just as the three sub-scores: ‘Activity’
(assessing the effects of breathlessness on mobility and
physical activity), ‘impacts’ (assessing the psychosocial
impact of disease), ‘Symptoms’ (assessing distress due to
respiratory symptoms). A change of 4 units was considered
to be clinically relevant (14,15).
The safety of the treatments was assessed by measuring
the vital signs (heart rate and blood pressure) before each
spirometry, and by recording adverse experiences (AE)
(nature, severity and causal relationship), as well as reasons
for premature treatment discontinuations.
STATISTICAL ANALYSIS
Data processing and statistical analyses were performed
using SAS under Windows release 6?12. The primary
ecacy variable was the mean change in morning predose
PEF for the entire treatment period. The calculation of the
minimum sample size required for the study was based on
this variable. Assuming an upper limit for the true standard
deviation of mean morning PEF of 50 lmin71 and the use
of a two-sided significance test at the 5% level, then a total
of 198 patients (99 per treatment) would have given the
study a power of 80% to detect a difference of 20 lmin71
between formoterol and ODS. Secondary ecacy end-
points included mean increase in evening predose PEF for
the entire treatment period, mean morning and evening pre-
dose PEF averaged 1-monthly, changes in morning pre-
dose FEV1 at visits 3, 4 and 5, day- and night-time use of
salbutamol, day- and night-time symptom scores and
SGRQ scores.
The analyses were carried out in the intent-to-treat
population, i.e. in all randomized patients with a post-
baseline ecacy measurement. Peak expiratory flow, use of
salbutamol and symptom scores were analysed by analysis
FIG. 1. Mean (+SEM) changes from baseline in morning
and evening peak expiratory flow (PEF) (* * *
P50?0001). &: formoterol; &: on demand salbutamol.
66 M. MOLIMARD ET AL.of covariance (ANCOVA) with treatment, centre and sex as
factors, and with the baseline value (run-in average) as a
covariate. For the primary variable (morning predose PEF
for the entire treatment period), treatment-by-centre,
treatment-by-baseline and treatment-by-sex interactions
were also tested. The same ANCOVA model as specified
above (without interactions) was used for predose FEV1
and vital signs.
Results
A total of 266 patients were screened, of whom 259 were
randomized at visit 2. Of the seven patients who
discontinued before the randomization, three failed to
fulfill the selection criteria, two withdrew their consent and
two were lost to follow-up. Thirty patients withdrew from
the study prematurely after the randomization (formoterol,
12; ODS, 18). The reasons for these premature discontinua-
tions were lost to follow-up (formoterol, five; ODS, seven),
adverse events (formoterol, three; ODS, three), withdrawal
of consent (formoterol, one; ODS, two), not meeting
protocol criteria (formoterol, one; ODS, three), unsatisfac-
tory therapeutic effect (formoterol, 0; ODS; three) and
administrative problems (formoterol, two; ODS, 0). Six
patients were excluded from the intent-to-treat ecacy
analysis because of the absence of ecacy data. The two
treatment groups were similar with respect to demo-
graphics, asthma history and lung function (Table 1).
LUNG FUNCTION
The mean increase (+SD) in morning PEF over the 3
months was significantly higher in the formoterol group
than in the ODS group: +25?7(+36?5) lmin71 and +4?5
(+32?7) lmin71 respectively (P50?0001). Formoterol alsoTABLE 1. Patient demographics, asthma duration, baseline lung
For
Demographics
Mean age + SD (years)
Sex (F:M)
Mean height +SD (cm) 1
Mean weight +SD (kg)
Smoking status: n(%)
Never
Past
Current
Mean asthma duration +SD (years)
Baseline lung function
Mean FEV1+SD (% of predicted value)
Mean PEF+SD (lmin71)
Morning 3
Evening 3
Mean reversibility +SD (% of predicted FEV1)induced a significantly higher mean increase in evening
predose PEF: +24?1 (+35?3) lmin71 and +0?5 (+31?5)
lmin71 respectively (P50?0001). The mean changes in
morning and evening PEF compared with baseline values
are shown in Fig. 1.function
moterol (n¼130) On-demand salbutamol (n¼129)
38.5+14.9 39.5+15.0
76:54 71:58
67?3+9?5 167?3+9?6
67?3+15?1 67?0+11?8
91 (70) 88 (68)
20 (15) 23 (18)
19 (15) 18 (14)
14?7+13?0 15?1+11?5
72?7+10?0 73?7+9?4
87?4+108?2 396?2+85?0
99?1+111?0 406?0+89?0
15?1+5?6 15?8+7?8
FIG. 2. Mean (+SEM) changes from baseline in FEV1 (* *
P50?01, * P50?05). &: formoterol; &: on demand
salbutamol.
FIG. 3. Mean (+SEM) percentages of days and nights with
no puffs of salbutamol (* * * P50?0001 vs. baseline). &:
formoterol; &: on demand salbutamol.
FIG. 4. Patterns of salbutamol use as rescue medication.
&: formoterol; &: on demand salbutamol.
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with formoterol at visits 3 and 5 (P50?01 and P50?05,
respectively). The mean changes in FEV1 compared with
baseline values are shown in Fig. 2.
SALBUTAMOL USE
Over the 3 months, the mean (+SD) number of puffs of
salbutamol during the day decreased from 1?2 (+1?46) to
0?4 (+0?65) in the formoterol group and increased from 1?0
(+1?24) to 1?1 (+1?29) in the ODS group. Similarly, the
mean (+SD) number of puffs of salbutamol during the night
changed from 0?7 (+0?85) to 0?2 (+0?46) and from 0?5
(+0?76) to 0?7 (+0?88), respectively.
The mean (+SD) changes from baseline in the number of
puffs of salbutamol during day and night respectively, were
70?8 (+1?32) and 70?4 (+0?72) with formoterol, and
+0?1 (+0?85) and + 0?1 (+0?69) with ODS (P50?0001
for day and night).
The percentages of days and nights with no puff of
salbutamol are shown in Fig. 3 and the rescue use patterns
in Fig. 4.
During the run-in period, 91% of the patients used
salbutamol at least once in the formoterol group and 85%
in the ODS group. Of these patients, 54% of the formoterol
patients and 20% of the ODS patients did not use salbutamol
throughout the 3-month treatment period or used it less than
once monthly. Conversely, 45% of the ODS patients used
salbutamol daily or at least once a week compared with only
15% of the patients in the formoterol group.
ASTHMA SYMPTOM SCORES
The mean (+SD) baseline daytime symptom score was 0?7
(+0?66) in the formoterol group and 0?6 (+0?66) in the
ODS group. Over the 3-month treatment period, the mean
decrease in this score was significantly higher with
formoterol (70?3+0?48) than with ODS (70?1+0?43)
(P50?0001). Similar changes were observed in night-time
symptom scores (baseline values: 0?5+0?54 and 0?3+0?54,changes vs. baseline: 70?1+0?43 and 0?0+0?35, respec-
tively) (P50?0001).
Over the 3 months, the increase in the mean (+SD)
percentage of symptom-free days was significantly higher in
the formoterol group (from 53?5+38?2% to 71?3+35?0%,
i.e. a 20% increase in symptom-free days) than in the ODS
group (from 56?8+38?2% to 63?4+36?0%) (P50?0001).
The respective values of the mean (+SD) percentages of
symptom-free nights were 68?2+ 33?8% to 81?7+ 28?4%
(i.e. a 33% increase in symptom-free nights) and
78?0+30?0% to 76?4+29?7% (P=0?003).
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After 3 months, the mean decreases in the SGRQ total
score and in the ‘activity’ and ‘symptoms’ sub-scores
statistically significantly exceeded the threshold for a
clinically relevant change in the formoterol group. The
mean decrease in the total SGQR score was significantly
higher with formoterol (76?4+10?0) than with ODS
(73?5+13?7) (P=0?05). The changes in the mean sub-
and total SGRQ scores are shown in Fig. 5.
SAFETY
At least one AE was reported by 47 (36%) and 46 (36%) of
the formoterol and ODS patients, respectively. Five
patients of the formoterol group (4%) and four patients
of the ODS group (3%) presented at least one drug-related
AE with no relevant differences between the two groups.
Drug-related AE induced premature withdrawal of the
treatment in two patients (2%) of the formoterol group and
in three patients (2%) of the ODS group. Bronchitis or
asthma worsening was reported in 17 patients (13%) and 20
patients (15%), respectively. No drug-related serious AE
was reported. No clinically relevant changes in heart rate or
blood pressure were observed in any group throughout the
study.
Discussion
Although a treatment with a long-acting bronchodilator is
recommended in patients with moderate persistent asthma
in addition to inhaled corticosteroids (2), some physicians
are reluctant about a continuous treatment with a long-
acting b2-agonist and prefer to limit the bronchodilator
therapy to a short-acting b2-agonist used on an on-demand
basis. The causes for the reticence about regular use of a
long-acting b2-agonist are various (safety, tolerance, loss of
asthma control, etc.) (16,17), despite the fact they have
never been demonstrated in large clinical studies. TheFIG. 5. Mean (with 95% confidence interval) changes in
sub- and total St George Hospital Respiratory Quest
(SGRQ) scores. The horizontal dotted line is the threshold
of clinically significant change in SGRQ scores. &:
formoterol; &: on demand salbutamol.results of this study demonstrate that, in patients with a
moderate persistent asthma, the addition of formoterol
12mg b.i.d. to treatment with inhaled corticosteroid and
ODS, reduces use of salbutamol, asthma symptoms and
improves lung function and quality of life.
Reduction in short-acting b2-agonist use is balanced by
the use of a long-acting b2-agonist so that the overall b2-
agonist consumption is not reduced by addition of
formoterol. However, as opposed to on-demand inhalation
of salbutamol, use of formoterol may be scheduled only in
the morning and evening, making it more convenient. The
time of requirement of on-demand therapy is not pre-
dictable. Consequently patients with only on-demand
salbutamol therapy take their treatment frequently and
only when dyspnoea is present. More than the absolute b2-
agonist consumption, the frequency of rescue medication
requirement is one of the major handicaps for patients. So
54% of patients in the formoterol group vs. 20% of patients
in the ODS group had to take rescue salbutamol less than
once a month, allowing a quite normal life. This contributes
to the clinically significant improvement in quality of
life observed in the formoterol group. The reduction in
rescue medication requirement observed with formoterol
may be partly explained by a protective effect of
formoterol. Indeed, ODS treatment being taken after
the beginning of chest discomfort has no protective
effect whereas a sustained bronchoprotective effect over
a 6-month period has been demonstrated for formoterol
(12). Subsequently Fitzgerald et al. demonstrated a reduc-
tion in the exacerbation rate in the formoterol group
compared to the salbutamol group in agreement with
the reduction in the exacerbation rate observed with
formoterol in the FACET study (18). The pattern of
exacerbation was however no different with or without
formoterol (19), confirming the lack of interaction of
formoterol on rescue medication observed on human
bronchi (20).
To the authors’, knowledge, this is the first study in
which formoterol has been compared with ODS only and
not with ODS in combination with a placebo matched to
formoterol. The open design of the study made this
comparison possible. Whereas the improvements in lung
function, symptom scores and salbutamol use observed
with formoterol are similar to those presented in previously
published studies (11,12,21,22), the results observed with
the ODS confirm the elimination of the placebo effect. In a
double-blind study comparing formoterol with ODS plus
placebo matched to formoterol, the reduction in salbutamol
use during the entire treatment period was 60% with
formoterol and 27% with ODS, i.e. almost half the effect of
formoterol (12). In the present study no change in
salbutamol use was found in the ODS group throughout
the 3-month treatment period. Comparable results in
symptom scores suggest the existence of a significant
placebo effect for these criteria of asthma control.
The improvement in quality of life observed in the
formoterol group at the end of this 3-month study
complement the traditional indicators of asthma ecacy.
A significant improvement in the total score of the St
George’s Hospital Respiratory Questionnaire has already
FORMOTEROL VERSUS ON -DEMAND SALBUTAMOL IN ASTHMA 69been found after longer treatment with formoterol (6
months) (23).
In conclusion, this study carried out in the conditions of
real practice shows that adding formoterol to treatment in
patients with moderate persistent asthma treated with ODS
and inhaled corticosteroid, results in improved lung
function, reduced symptoms and rescue salbutamol use,
and an improved quality of life.
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